首页> 外文期刊>Journal of molecular histology >Polydatin and polydatin-loaded chitosan nanoparticles attenuate diabetic cardiomyopathy in rats
【24h】

Polydatin and polydatin-loaded chitosan nanoparticles attenuate diabetic cardiomyopathy in rats

机译:多达辛和多达凡载壳聚糖纳米粒子在大鼠中衰减糖尿病心肌病

获取原文
获取原文并翻译 | 示例
           

摘要

Hyperglycemia is associated with impairment of heart function. The current study aimed to investigate the ameliorative effect of polydatin-loaded chitosan nanoparticles (PD-CSNPs), polydatin (PD) and metformin (MET) on diabetic cardiomyopathy in rats. Rats divided into six groups; normal-control, diabetic-control, diabetic + CSNPs (diabetic rats treated with 50 mg/kg blank chitosan nanoparticles), diabetic + PD-CSNPs (diabetic rats treated with PD-CSNPs equivalent to 50 mg/kg of polydatin), diabetic + PD (diabetic rats given 50 mg/kg polydatin), diabetic + MET (diabetic rats given 100 mg/kg metformin), orally and daily for 4 weeks. Treatment of diabetic rats with PD-CSNPs, PD and MET showed a significant reduction in the values of glucose and glycosylated hemoglobin with improvement in heart function biomarkers through decreasing serum creatine kinase and creatine kinase myocardial band activities compared to diabetic control. The treatment agents also suppressed the elevated lipid peroxidation product, increased values of glutathione content, superoxide dismutase, superoxide peroxidase, and catalase activities in the heart of diabetic treated rats. Furthermore, PD-CSNPs, PD and MET decreased heart tissue levels of a pro-inflammatory cytokine; tumor necrosis factor-alpha and nuclear factor-kappa beta, upregulation of heart gene expressions; nuclear factor erythroid 2-related factor 2 and heme oxygenase-1. Histological and ultrastructural examinations revealed the ameliorative effect of PD-CSNPs, PD and MET against the harmful of diabetic cardiomyopathy by reducing the cardiac fibers, necrotic cardiac myocytes, inflammatory cell infiltration, and the arrangement of the myofibrils and intercalated discs. In conclusion, the new formula of PD-CSNPs was more effective than PD and MET in amelioration the diabetic cardiomyopathy through its antioxidant, anti-inflammatory and prolonged-release properties.
机译:高血糖与心功能损害有关。本研究旨在探讨虎杖苷壳聚糖纳米粒(PD-CSNP)、虎杖苷(PD)和二甲双胍(MET)对大鼠糖尿病心肌病的改善作用。大鼠分为六组;正常对照组、糖尿病对照组、糖尿病+CSNP(用50 mg/kg空白壳聚糖纳米粒治疗的糖尿病大鼠)、糖尿病+PD-CSNP(用相当于50 mg/kg虎杖苷的PD-CSNP治疗的糖尿病大鼠)、糖尿病+PD(用50 mg/kg虎杖苷治疗的糖尿病大鼠)、糖尿病+MET(用100 mg/kg二甲双胍治疗的糖尿病大鼠),口服和每日4周。与糖尿病对照组相比,用PD-CSNP、PD和MET治疗糖尿病大鼠,通过降低血清肌酸激酶和肌酸激酶心肌带活性,血糖和糖化血红蛋白值显著降低,心脏功能生物标志物改善。这些治疗剂还抑制了糖尿病大鼠心脏中升高的脂质过氧化产物、谷胱甘肽含量、超氧化物歧化酶、超氧化物过氧化物酶和过氧化氢酶活性的增加。此外,PD-CSNP、PD和MET降低了心脏组织中促炎细胞因子的水平;肿瘤坏死因子-α和核因子-κ-β,心脏基因表达上调;核因子红系2相关因子2和血红素加氧酶-1。组织学和超微结构检查显示,PD-CSNP、PD和MET通过减少心肌纤维、坏死心肌细胞、炎性细胞浸润、肌原纤维和闰盘的排列来改善糖尿病心肌病的危害。综上所述,在改善糖尿病心肌病方面,PD-CSNPs的新配方通过其抗氧化、抗炎和缓释特性比PD和MET更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号